Connect with us

Global Market

Cholesterol Screening Market Recent Study including Growth Factors, Applications, Regional Analysis, Key Players and Forecast till 2027

Published

on

Press Release

Cholesterol Screening Market Research has offered exhaustive analysis of Manufacturers, Suppliers, Regions, Type and Application, Forecast to 2027. And also provides essential study on the current status of the market, cover market size with respect to valuation as sales volume and providing a precise prediction of the market scenario over the forecast period from 2020 to 2027.

“Cholesterol Screening Market research report delivers a comprehensive study on production capacity, consumption, import and export for all major regions across the world. Report provides is a professional inclusive study on the current state for the market. Analysis and discussion of important industry like market trends, size, share, growth estimates are mentioned in the report.”

Download Sample PDF Of [email protected] https://www.alliedmarketresearch.com/request-toc-and-sample/3722

Global Market Size of Cholesterol Screening Market is $XX million in 2019 with XX CAGR, and it is expected to reach $XX million by the end of 2027 with a CAGR of XX% from 2020 to 2027.

The report provides revenue forecast with sales, sales growth rate, and revenue growth rate forecasts of the global Cholesterol Screening market. The forecasts are also provided with respect to the product, application, and regional segments of the market. The forecasts are provided to understand the future outlook and prospects for the market.

Major Key Players: –

The key players operating in this market include: ACM Medical Laboratory, Clinical Reference Laboratory, Inc., Laboratory Corporation of America Holdings, Eurofins Scientific, Quest Diagnostics Incorporated, SYNLAB International GmbH, Fresenius Medical Care Holdings, Inc., and others

The leading companies in Global Cholesterol Screening Market are analyzed in the report along with their business overview, operations, financial analysis, SWOT profile and Cholesterol Screening products and services.

The report lays emphasis on the key trends and opportunities that may emerge in the near future and positively impact the overall industry growth. Additionally, challenges and restraining factors that are likely to curb the growth in the years to come are put forth by the analysts to prepare the manufacturers for future challenges in advance.

Market Segmentation:

The report presents in-depth insights into each of the leading Cholesterol Screening end user verticals along with annual forecasts to 2027.

By End Users

  • Physicians/Providers
  • Hospitals
  • Managed Care Organizations (MCOs)
  • Government Agencies
  • Accountable Care Organizations (ACOs)
  • Integrated Delivery Networks (IDNs)

By Geography

  • North America
  • Europe
  • Asia Pacific
  • LAMEA

The market is evaluated based on its regional penetration, explaining the performance of the market in each regional market covering regions such as North America (United States, Canada and Mexico), Europe (Germany, France, UK, Russia and Italy), Asia-Pacific (China, Japan, Korea, India and Southeast Asia), South America (Brazil, Argentina, Colombia), Middle East and Africa (Saudi Arabia, UAE, Egypt, Nigeria and South Africa)

Inquiry for Buying [email protected] https://www.alliedmarketresearch.com/purchase-enquiry/3722

About Us:

Allied Market Research (AMR) is a full-service market research and business-consulting wing of Allied Analytics LLP based in Portland, Oregon. Allied Market Research provides global enterprises as well as medium and small businesses with unmatched quality of “Market Research Reports” and “Business Intelligence Solutions.” AMR has a targeted view to provide business insights and consulting to assist its clients to make strategic business decisions and achieve sustainable growth in their respective market domain.

We are in professional corporate relations with various companies and this helps us in digging out market data that helps us generate accurate research data tables and confirms utmost accuracy in our market forecasting. Each and every data presented in the reports published by us is extracted through primary interviews with top officials from leading companies of domain concerned. Our secondary data procurement methodology includes deep online and offline research and discussion with knowledgeable professionals and analysts in the industry.

Contact:
David Correa
5933 NE Win Sivers Drive
#205, Portland, OR 97220
United States
USA/Canada (Toll Free): +1-800-792-5285, +1-503-894-6022, +1-503-446-1141
UK: +44-845-528-1300
Hong Kong: +852-301-84916
India (Pune): +91-20-66346060

Continue Reading

Global Market

Global Type 1 Hyperlipoproteinemia Drugs Market is expected to grow at a CAGR of 8.8% from 2020 to 2027

Published

on

Press Release

Type 1 hyperlipoproteinemia is also called familial lipoprotein lipase deficiency is an inherited genetic disorder, it is a rare disease with a global prevalence rate of 1 to 2 per 1,000,000 people. Currently the drugs used for its clinical treatment are Alipogene Tiparvovec, lomitapide mesylate, pradigastat sodium, etc.

Hypertriglyceridemia is dominating the indication segment for the type 1 hyperlipoproteinemia drug market. It is manifested by the triglyceride blood serum level of above 500mg/dl. The excess levels of triglyceride and chylomicrons in the blood are due to a lack of familial lipoprotein lipase deficiency and familial apolipoprotein C-II deficiency in certain cases. In the later stage of life it results in cardiovascular complications in the patients. Acute pancreatitis is the first clinical manifestation occurring in patients suffering from type 1 hyperlipoproteinemia. Intense bouts of abdominal pain occur due to the inflammation of the pancreas and it possesses a great risk of diabetes in the later stage of life. Eruptive xanthomas are the fastest growing indication segment, primarily due to its occurrence in approximately 50% of the patients having familial lipoprotein lipase deficiency, small localized bumps, and plaques appear on the skin suffer on account of the deposition of lipids in the tendons, skin and subcutaneous tissues.

Browse the full report Type 1 Hyperlipoproteinemia Drugs Market – Global Industry Analysis, Size, Share, Growth, Trends, and Forecast, 2020 – 2027 at https://www.atlanticmarketresearch.com/type-1-hyperlipoproteinemia-drugs-market

Hospital pharmacy is dominating the distribution channel segment for the type 1 hyperlipoproteinemia drug market. The availability of hospital pharmacist is vital in order to prepare accurate drug posology prescribed for the treatment of type 1 hyperlipoproteinemia, in order to prevent any drug-related side effects. The retail pharmacy will be the fastest-growing segment during the forecast period in the developing countries owing to its ability to provide prescribed and OTC medicines 24/7 especially in remote locations and relatively low cost.

North America is reigning the geographical segment for the type 1 hyperlipoproteinemia drugs market. The rising prevalence of acute pancreatitis is primarily driving its market growth. As per the latest statistics provided by the Center for Disease Control and Prevention (CDC), approximately one-fourth of theU.S. adult citizens are reported to be suffering from hypertriglyceridemia. Further diagnosis has revealed that it is linked with chylomicron abnormalities in the human blood. The supportive regulatory environment provided by the USFDA by awarding fast track designation status for the drug development to be used in the treatment of rare diseases accentuates the type 1 hyperlipoproteinemia drug market. Europe is the second-largest market owing to the strategic partnership between the academic research institutes and biopharmaceutical companies to develop a gene therapy to treat lipoprotein lipase disorders. Furthermore affordable reimbursement scenario for the drugs employed in the treatment of type 1 hyperlipoproteinemia further propels its market growth in the region. Asia Pacific is set to record magnificent market growth in the near future on account of the developing healthcare infrastructure and large funds allotted by the healthcare agencies to develop novel medicines for the treatment of familial liposome lipase deficiency.

Biopharmaceutical companies actively engaged in providing medicines for the treatment of type 1 hyperlipoproteinemia are Aegerion Pharmaceuticals, Inc., Novartis AG., Isis Pharmaceuticals, Inc., uniQure N.V., Catabasis Pharmaceuticals, Inc., Anji Pharma, Chiesi Farmaceutici., Arrowhead Pharmaceuticals., Ionis Pharmaceuticals, Inc., and BASF SE.

Market Key Takeaways:

  • A constant rise in the number of patients suffering with lipoprotein lipase deficiency
  • Proactive role adopted by the global healthcare regulatory agencies for the novel drug development for the treatment of type 1 hyperlipoproteinemia
  • Affordable reimbursement scenario for the costly medication used in the treatment of rare disease worldwide

About Atlantic Market Research

Atlantic Market Research is the largest provider of market research and consulting services.

Research and consulting services of Atlantic Market Research help businesses across the globe navigate the challenges in a rapidly growing marketplace with confidence. Our customized and syndicated market research reports deliver sufficient insights that drive sustainable growth.

Contact:
Mr. Trevor Wilson
Atlantic Market Research
911 Central Ave #268
Albany, NY 12206, USA

Website: https://www.atlanticmarketresearch.com
Email: [email protected]

Continue Reading

Global Market

Global Plasminogen Market Is Expected To Grow At A CAGR Of 4.1% From 2020 To 2027

Published

on

Press Release

Plasminogen is an inactive form of plasmin released by the liver in the systemic circulation, it is a serine protease and its objective is the dissolution of fibrin blood clots. Acquired and hereditary plasminogen deficiency increases the risk of thromboembolic disease.

Thrombosis is dominating the application segment for the plasminogen market. Rising prevalence of pulmonary embolism in elderly patients and a significant increase in the inherited plasminogen deficiency of plasminogen together drive the market growth.  As per the recent research findings provided by the World Health Organization (WHO), the prevalence rate associated with deep vein thrombosis is 1 to 2 per 1000 people each year. Ischemic heart disease will be showcasing remarkable market growth during the forecast period owing to the constant rise in the adoption of an unhealthy lifestyle, diet, stress, and high consumption of tobacco and alcohol worldwide. As per the latest research citings provided by the World Health Organization (WHO), approximately 15 million people suffer from stroke throughout the globe each year.

Hospitals and clinics are presently leading the end-user segment for the plasminogen market. The key factor responsible for its positive market growth is the rising prevalence of ischemic heart diseases and venous thromboembolism worldwide. Patients need to be immediately hospitalized in the critical care unit to remove the clot present in the venous system to prevent fatality and mortality associated with the disease. Ambulatory surgical centers will be growing at a rampant market growth in the near future to its ability to provide emergency medical aid to patients suffering from myocardial infarction in remote locations.

Browse the full report Plasminogen Market – Global Industry Analysis, Size, Share, Growth, Trends, and Forecast, 2020 – 2027 at https://www.atlanticmarketresearch.com/plasminogen-market

North America is currently spearheading the geography segment for the plasminogen market. The major factor associated with its market dominance is the rising prevalence of deep vein thrombosis in the region. According to the latest statistics provided by the Center for Disease Control and Prevention (CDC), approximately the prevalence rate associated with deep vein thrombosis is 1 to 2 per 1,000 per year in the United States. Affordable reimbursement scenario and supportive regulatory environment provided by the USFDA pertaining to the manufacture and sale of plasminogen provides a boost to the market growth in the region. Europe stood 2nd in the regional segment for the plasminogen market on account of the rising prevalence of ischemic heart disease in the European Union. As per the latest research citings presented by the European Heart Network (EHN), each year cardiovascular disease causes approximately 3.9 million deaths in the region. Asia Pacific is anticipated to be the fastest-growing regional segment during the forecast period owing to the developing healthcare infrastructure and constant rise in the medical tourism industry in the Asia Pacific region.

Biopharmaceutical manufacturers actively engaged in the production of plasminogen are Diapharma, Kedrion S.p.A., Liminal BioSciences, Genentech, Inc. (Roche), Boehringer Ingelheim, Kyowa Hakko Kirin, Omeros Corporation, Bayer AG, Cadila Healthcare Ltd, and Merck & Co.

Market Key Takeaway:

  • Rising prevalence of ischemic heart diseases worldwide
  • Significant increase in the number of people suffering from venous thromboembolism throughout the globe
  • The supportive regulatory environment provided by the global healthcare agencies regarding the manufacturing and sale of plasminogen

About Atlantic Market Research

Atlantic Market Research is the largest provider of market research and consulting services.

Research and consulting services of Atlantic Market Research help businesses across the globe navigate the challenges in a rapidly growing marketplace with confidence. Our customized and syndicated market research reports deliver sufficient insights that drive sustainable growth.

Contact:
Mr. Trevor Wilson
Atlantic Market Research
911 Central Ave #268
Albany, NY 12206, USA

Website: https://www.atlanticmarketresearch.com
Email: [email protected]

Continue Reading

Global Market

Global Ornithine Transcarbamylase Deficiency Market is expected to grow at a CAGR of 12.4% from 2020 to 2027

Published

on

Press Release

Ornithine transcarbamylase is one of the six enzymes which is vital in the removal of excess nitrogen in the form of ammonia from the human blood. It is categorized as an inherited X- linked genetic disorder that occurs in more in the males as compared to the females. Lack of treatment will result in hyperammonemia which will cause coma, lethargy, loss of appetite and vomiting, etc.

Ammonia scavenging drugs are leading the treatment segment for the ornithine transcarbamylase (OTC) deficiency market. Prodrug such as glycerol phenylbutyrate and sodium phenylbutyrate forms an acetyl conjugate with the nitrogen present in the glutamine via the acetylation process in the detoxification organs such as liver and kidneys in order to facilitate the excretion of excess nitrogen via the urine. Gene therapy is going to register faster market growth in the near future owing to the strong product pipeline for the treatment of ornithine transcarbamylase (OTC) deficiency. Ultragenyx Pharmaceutical, Inc., has developed DTX-301 to deliver the OTC gene expression in a durable fashion to reduce its complications associated with clinical manifestation of this rare disease

Browse the full report Ornithine Trancarbamylase Deficiency Market – Global Industry Analysis, Size, Share, Growth, Trends, and Forecast, 2020 – 2027 at https://www.atlanticmarketresearch.com/ornithine-transcarbamylase-deficiency-market

Hospital pharmacy is currently leading the distribution channel segment for ornithine transcarbamylase (OTC) deficiency market. The vital factor which is related to its positive market growth is the presence of a hospital pharmacist for dispensing the medicines with precise posology prescribed by the physicians for the treatment of urea cycle disorder associated with ornithine transcarbamylase (OTC) deficiency. Retail pharmacy is going to embark on rampant market growth during the forecast period on account of the availability of ammonia scavenging drugs at a discounted price. Going forward the government healthcare agencies will be providing gene therapy drugs at a subsidized rate in the retail pharmacy to cater medical needs of low and middle-income groups households.

North America is dominating the geography segment for ornithine transcarbamylase (OTC) deficiency market. Significant increase in the number of newborn male babies suffering from ornithine transcarbamylase deficiency primarily drives its market growth in the region. Additionally domicile of major players such as Selecta Biosciences, Inc., Horizon Therapeutics, Plc., Phase Rx, Inc., etc. further propels the market growth in the region. Europe holds the second-largest market in the geography segment for ornithine transcarbamylase deficiency market. As per the European Commission report the prevalence rate of ornithine transcarbamylase deficiency in the neonates is 9 per 100,000 live births. The supportive regulatory environment provided by the European Medical Agency (EMA), by designating fast track status to the drug development for the treatment of ornithine transcarbamylase deficiency in the region. Asia Pacific is keen to register excellent market growth during the forecast period owing to the increasing trend of hospital pharmacy affiliated with corporate hospitals and increasing funds invested by government healthcare agencies for the drug development of rare diseases.

Biopharmaceutical companies actively engaged in providing medicines for the treatment of ornithine transcarbamylase deficiency are Merck KGaA., Phase Rx, Inc., Promethera Biosciences SA., Horizon Therapeutics, plc., Lucane Pharma SA., Swedish Orphan Biovitrum AB, Selecta Biosciences, Inc., Translate Bio, Inc., Ultragenyx Pharmaceutical, Inc., and Unicyte AG.

Market Key Takeaways:

  • Constant rise in the neonates worldwide suffering urea cycle disorder associated with ornithine transcarbamylase deficiency
  • Strong product pipeline comprising of gene therapy and stem cells transplantation to treat ornithine transcarbamylase (OTC) deficiency
  • Supportive regulatory environment provided by the healthcare agencies throughout the globe by awarding fast track designation for the drug development in treating OTC deficiency which is an orphan disease

About Atlantic Market Research

Atlantic Market Research is the largest provider of market research and consulting services.

Research and consulting services of Atlantic Market Research help businesses across the globe navigate the challenges in a rapidly growing marketplace with confidence. Our customized and syndicated market research reports deliver sufficient insights that drive sustainable growth.

Contact:
Mr. Trevor Wilson
Atlantic Market Research
911 Central Ave #268
Albany, NY 12206, USA

Website: https://www.atlanticmarketresearch.com
Email: [email protected]

Continue Reading

Trending

Copyright © 2019 Melanian News